See more : Clockchain AG (U1DA.F) Income Statement Analysis – Financial Results
Complete financial analysis of Chong Kun Dang Pharmaceutical Corp. (185750.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chong Kun Dang Pharmaceutical Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- JanOne Inc. (JAN) Income Statement Analysis – Financial Results
- Saudi Industrial Development Co. (2130.SR) Income Statement Analysis – Financial Results
- Intrepid Potash, Inc. (IPI) Income Statement Analysis – Financial Results
- Prakash Woollen & Synthetic Mills Limited (PWASML.BO) Income Statement Analysis – Financial Results
- Shindaeyang Paper Co., Ltd. (016590.KS) Income Statement Analysis – Financial Results
Chong Kun Dang Pharmaceutical Corp. (185750.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ckdpharm.com
About Chong Kun Dang Pharmaceutical Corp.
Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,669.40B | 1,488.34B | 1,343.56B | 1,303.01B | 1,079.34B | 956.22B | 884.36B | 831.99B | 592.49B | 544.13B | 86.32B |
| Cost of Revenue | 1,007.20B | 945.71B | 847.74B | 813.87B | 675.06B | 575.82B | 524.71B | 497.10B | 296.31B | 263.79B | 40.09B |
| Gross Profit | 662.20B | 542.64B | 495.82B | 489.14B | 404.28B | 380.40B | 359.66B | 334.89B | 296.18B | 280.34B | 46.23B |
| Gross Profit Ratio | 39.67% | 36.46% | 36.90% | 37.54% | 37.46% | 39.78% | 40.67% | 40.25% | 49.99% | 51.52% | 53.56% |
| Research & Development | 140.23B | 176.32B | 163.28B | 146.66B | 98.62B | 77.03B | 65.05B | 67.18B | 57.75B | 42.87B | 11.18B |
| General & Administrative | 24.99B | 22.56B | 20.24B | 17.88B | 21.90B | 30.43B | 26.32B | 28.88B | 28.07B | 22.96B | 4.99B |
| Selling & Marketing | 106.38B | 93.89B | 82.48B | 73.49B | 76.83B | 86.73B | 77.46B | 72.44B | 66.51B | 66.80B | 8.78B |
| SG&A | 131.38B | 116.45B | 102.71B | 91.37B | 98.73B | 117.16B | 103.78B | 101.31B | 94.58B | 89.75B | 13.77B |
| Other Expenses | 143.99B | 139.96B | 135.07B | 127.17B | 132.35B | -3.98B | 811.80M | 2.30B | -21.79B | -687.66M | -382.59M |
| Operating Expenses | 415.60B | 432.73B | 401.06B | 365.20B | 329.70B | 304.66B | 281.89B | 273.64B | 253.48B | 226.41B | 38.69B |
| Cost & Expenses | 1,422.72B | 1,378.44B | 1,248.80B | 1,179.07B | 1,004.76B | 880.48B | 806.60B | 770.74B | 549.79B | 490.20B | 78.78B |
| Interest Income | 5.79B | 2.14B | 716.22M | 1.28B | 854.48M | 584.72M | 609.47M | 143.99M | 649.54M | 942.36M | 60.32M |
| Interest Expense | 9.27B | 6.85B | 4.03B | 3.87B | 3.15B | 2.71B | 3.51B | 4.17B | 4.35B | 5.37B | 950.64M |
| Depreciation & Amortization | 37.03B | 33.51B | 27.38B | 23.69B | 22.96B | 21.14B | 21.90B | 23.85B | 22.68B | 20.55B | 3.28B |
| EBITDA | 287.62B | 143.50B | 112.61B | 149.40B | 97.93B | 92.19B | 100.01B | 84.81B | 42.17B | 74.40B | 10.24B |
| EBITDA Ratio | 17.23% | 9.73% | 8.41% | 11.55% | 9.31% | 9.81% | 11.29% | 10.54% | 7.50% | 13.66% | 11.84% |
| Operating Income | 246.60B | 109.91B | 94.76B | 123.94B | 74.58B | 75.74B | 77.76B | 61.25B | 42.71B | 53.93B | 7.54B |
| Operating Income Ratio | 14.77% | 7.38% | 7.05% | 9.51% | 6.91% | 7.92% | 8.79% | 7.36% | 7.21% | 9.91% | 8.73% |
| Total Other Income/Expenses | -5.00B | -12.74B | -14.16B | -2.10B | -2.75B | -7.40B | -3.17B | -4.46B | -27.57B | -5.45B | -1.53B |
| Income Before Tax | 241.60B | 97.17B | 80.59B | 121.84B | 71.82B | 68.34B | 74.60B | 56.79B | 15.14B | 48.48B | 6.01B |
| Income Before Tax Ratio | 14.47% | 6.53% | 6.00% | 9.35% | 6.65% | 7.15% | 8.44% | 6.83% | 2.55% | 8.91% | 6.96% |
| Income Tax Expense | 28.00B | 17.19B | 38.24B | 31.43B | 18.85B | 26.64B | 20.87B | 15.84B | 21.91B | 13.33B | 1.59B |
| Net Income | 212.52B | 80.95B | 42.72B | 91.63B | 53.88B | 42.40B | 53.81B | 40.95B | -6.77B | 35.15B | 4.42B |
| Net Income Ratio | 12.73% | 5.44% | 3.18% | 7.03% | 4.99% | 4.43% | 6.08% | 4.92% | -1.14% | 6.46% | 5.12% |
| EPS | 16.70K | 6.61K | 3.43K | 7.32K | 4.30K | 3.38K | 4.07K | 3.25K | -537.28 | 2.79K | 350.72 |
| EPS Diluted | 16.70K | 6.61K | 3.43K | 7.32K | 4.30K | 3.38K | 4.07K | 3.25K | -537.28 | 2.79K | 350.72 |
| Weighted Avg Shares Out | 12.72M | 12.25M | 12.44M | 12.52M | 12.53M | 12.53M | 13.23M | 12.60M | 12.61M | 12.60M | 12.59M |
| Weighted Avg Shares Out (Dil) | 12.72M | 12.25M | 12.44M | 12.52M | 12.53M | 12.53M | 13.23M | 12.60M | 12.61M | 12.60M | 12.59M |
Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication
Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
Source: https://incomestatements.info
Category: Stock Reports